Abbott Reports Strong Q3 Results, Reaffirms 2025 Outlook
Abbott Laboratories announced strong third-quarter results on October 15, 2025, reaffirming its full-year 2025 financial outlook. The company reported organic sales growth of 7.5% driven by its Medical Devices division.
**Abbott Laboratories reported strong third-quarter financial results on October 15, 2025, reaffirming its full-year 2025 financial outlook. The company announced total sales of $11.4 billion, a 6.9% increase from the previous year.
The Medical Devices segment was a key driver, achieving double-digit organic growth of 12.5% for the eleventh consecutive quarter, with sales reaching $5.4 billion. Within this segment, Diabetes Care saw a 16.2% organic increase, and Rhythm Management posted a 13.0% gain.
Abbott reiterated its guidance for full-year 2025, expecting organic sales growth between 7.5% and 8.0% for its base business. The company anticipates adjusted diluted earnings per share (EPS) to be in the range of $5.12 to $5.18, representing double-digit growth at the midpoint.
In addition to financial performance, Abbott highlighted regulatory and product advancement milestones. The Navitor™ transcatheter aortic valve implantation system received CE Mark for an expanded indication, and the TriClip® minimally invasive treatment for tricuspid valve disease gained regulatory approval in Japan.